{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T01:34:51Z","timestamp":1790386491722,"version":"4.1.0"},"reference-count":88,"publisher":"MDPI AG","issue":"9","license":[{"start":{"date-parts":[[2022,4,27]],"date-time":"2022-04-27T00:00:00Z","timestamp":1651017600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>FMS-like tyrosine kinase 3 (FLT3) is a receptor tyrosine kinase family member. Mutations in FLT3, as well known, represent the most common genomic alteration in acute myeloid leukemia (AML), identified in approximately one-third of newly diagnosed adult patients. In recent years, this has represented an important therapeutic target. Drugs such as midostaurin, gilteritinib, and sorafenib, either alone in association with conventional chemotherapy, play a pivotal role in AML therapy with the mutated FLT3 gene. A current challenge lies in treating forms of AML with extramedullary localization. Here, we describe the general features of myeloid sarcoma and the ability of a targeted drug, i.e., gilteritinib, approved for relapsed or refractory disease, to induce remission of these extramedullary leukemic localizations in AML patients with FLT3 mutation, analyzing how in the literature, there is an important development of cases describing this promising potential for care.<\/jats:p>","DOI":"10.3390\/cancers14092186","type":"journal-article","created":{"date-parts":[[2022,4,27]],"date-time":"2022-04-27T13:40:57Z","timestamp":1651066857000},"page":"2186","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":24,"title":["Target Therapy for Extramedullary Relapse of FLT3-ITD Acute Myeloid Leukemia: Emerging Data from the Field"],"prefix":"10.3390","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9510-4755","authenticated-orcid":false,"given":"Andrea","family":"Duminuco","sequence":"first","affiliation":[{"name":"Postgraduate School of Hematology, University of Catania, 95123 Catania, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cinzia","family":"Maugeri","sequence":"additional","affiliation":[{"name":"Division of Hematology, A.O.U. \u201cPoliclinico G.Rodolico-S.Marco\u201d, 95123 Catania, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marina","family":"Parisi","sequence":"additional","affiliation":[{"name":"Division of Hematology, A.O.U. \u201cPoliclinico G.Rodolico-S.Marco\u201d, 95123 Catania, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisa","family":"Mauro","sequence":"additional","affiliation":[{"name":"Division of Hematology, A.O.U. \u201cPoliclinico G.Rodolico-S.Marco\u201d, 95123 Catania, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo Fabio","family":"Fiumara","sequence":"additional","affiliation":[{"name":"Division of Hematology, A.O.U. \u201cPoliclinico G.Rodolico-S.Marco\u201d, 95123 Catania, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valentina","family":"Randazzo","sequence":"additional","affiliation":[{"name":"Division of Hematology & Bone Marrow Transplantation, Ospedali Riuniti Villa Sofia-Cervello, 90146 Palermo, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Domenico","family":"Salemi","sequence":"additional","affiliation":[{"name":"Division of Hematology & Bone Marrow Transplantation, Ospedali Riuniti Villa Sofia-Cervello, 90146 Palermo, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cecilia","family":"Agueli","sequence":"additional","affiliation":[{"name":"Division of Hematology & Bone Marrow Transplantation, Ospedali Riuniti Villa Sofia-Cervello, 90146 Palermo, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1859-6319","authenticated-orcid":false,"given":"Giuseppe Alberto","family":"Palumbo","sequence":"additional","affiliation":[{"name":"Postgraduate School of Hematology, University of Catania, 95123 Catania, Italy"},{"name":"Division of Hematology, A.O.U. \u201cPoliclinico G.Rodolico-S.Marco\u201d, 95123 Catania, Italy"},{"name":"Department of Biomedical and Biotechnological Sciences, University of Catania, 95123 Catania, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandra","family":"Santoro","sequence":"additional","affiliation":[{"name":"Division of Hematology & Bone Marrow Transplantation, Ospedali Riuniti Villa Sofia-Cervello, 90146 Palermo, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Di Raimondo","sequence":"additional","affiliation":[{"name":"Division of Hematology, A.O.U. \u201cPoliclinico G.Rodolico-S.Marco\u201d, 95123 Catania, Italy"},{"name":"Department of Chirurgia Generale e Specialit\u00e0 Medico-Chirurgiche, University of Catania, 95123 Catania, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1922-5157","authenticated-orcid":false,"given":"Calogero","family":"Vetro","sequence":"additional","affiliation":[{"name":"Division of Hematology, A.O.U. \u201cPoliclinico G.Rodolico-S.Marco\u201d, 95123 Catania, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2022,4,27]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"2021030","DOI":"10.4084\/MJHID.2021.030","article-title":"Extramedullary Involvement in Acute Myeloid Leukemia. A Single Center Ten Years\u2019 Experience","volume":"13","author":"Fianchi","year":"2021","journal-title":"Mediterr. J. Hematol. Infect. Dis."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.clml.2017.02.027","article-title":"Myeloid Sarcoma: Presentation, Diagnosis, and Treatment","volume":"17","author":"Almond","year":"2017","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1643","DOI":"10.1182\/blood.V90.4.1643","article-title":"Expression of the Neural Cell Adhesion Molecule CD56 Is Associated With Short Remission Duration and Survival in Acute Myeloid Leukemia With t(8; 21)(q22; q22)","volume":"90","author":"Baer","year":"1997","journal-title":"Blood"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"2107","DOI":"10.1002\/1097-0142(19940415)73:8<2107::AID-CNCR2820730815>3.0.CO;2-W","article-title":"Recurrent Granulocytic Sarcoma An Unusual Variation of Acute Myelogenous Leukemia Associated with 8; 21 Chromosomal Translocation and Blast Expression of the Neural Cell Adhesion Molecule","volume":"73","author":"Byrd","year":"1994","journal-title":"Cancer"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1126\/science.3576199","article-title":"Neural cell adhesion molecule: Structure, immunoglobulin-like domains, cell surface modulation, and alternative RNA splicing","volume":"236","author":"Cunningham","year":"1987","journal-title":"Science"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"3544","DOI":"10.1200\/JCO.2016.67.5892","article-title":"Extramedullary disease in adult acute myeloid leukemia is common but lacks independent significance: Analysis of patients in ECOG-ACRIN cancer research group trials, 1980\u20132008","volume":"34","author":"Ganzel","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1002\/ajh.20526","article-title":"Expression of MAC-1 (CD11b) in acute myeloid leukemia (AML) is associated with an unfavorable prognosis","volume":"81","author":"Graf","year":"2006","journal-title":"Am. J. Hematol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1007\/s00277-014-2082-4","article-title":"Correlation of CD11b and CD56 expression in adult acute myeloid leukemia with cytogenetic risk groups and prognosis","volume":"93","author":"Granada","year":"2014","journal-title":"Ann. Hematol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1309\/AJCP1ZA7HYZKAZHS","article-title":"Myeloid sarcoma: Extramedullary manifestation of myeloid disorders","volume":"132","author":"Campidelli","year":"2009","journal-title":"Am. J. Clin. Pathol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1309\/AJCPO58YWIBUBESX","article-title":"Extramedullary Manifestations of Myeloid Neoplasms","volume":"144","author":"Wilson","year":"2015","journal-title":"Am. J. Clin. Pathol."},{"key":"ref_11","unstructured":"(2022, January 25). PET-Imaging as a Useful Tool for Early Detection of the Relapse Site in the Management of Primary Myeloid Sarcoma|Haematologica. Available online: https:\/\/www.haematologica.org\/article\/view\/4265."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/S1095-0397(01)00056-5","article-title":"Detection of extramedullary infiltrates in acute myelogenous leukemia with whole-body positron emission tomography and 2-deoxy-2-[18F]-fluoro-D-glucose","volume":"4","author":"Kuenzle","year":"2002","journal-title":"Mol. Imaging Biol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"287","DOI":"10.5144\/0256-4947.2001.287","article-title":"The value of CD34, myeloperoxidase and chloroacetate esterase (Leder) stain in the diagnosis of granulocytic sarcoma","volume":"21","author":"Mourad","year":"2001","journal-title":"Ann. Saudi Med."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1097\/00000478-199310000-00006","article-title":"Extramedullary myeloid cell tumors. An immunohistochemical and morphologic study of 28 cases","volume":"17","author":"Traweek","year":"1993","journal-title":"Am. J. Surg. Pathol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1038\/sj.leu.2404491","article-title":"Myeloid sarcoma: Clinico-pathologic, phenotypic and cytogenetic analysis of 92 adult patients","volume":"21","author":"Pileri","year":"2007","journal-title":"Leukemia"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.biopha.2012.10.014","article-title":"Is there a \u201cgold\u201d standard treatment for patients with isolated myeloid sarcoma?","volume":"67","author":"Antic","year":"2013","journal-title":"Biomed. Pharmacother."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.1002\/cncr.10399","article-title":"Comparison in treatments of nonleukemic granulocytic sarcoma: Report of two cases and a review of 72 cases in the literature","volume":"94","author":"Yamauchi","year":"2002","journal-title":"Cancer"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"4238","DOI":"10.1182\/bloodadvances.2019000647","article-title":"How should we diagnose and treat blastic plasmacytoid dendritic cell neoplasm patients?","volume":"3","author":"Vidal","year":"2019","journal-title":"Blood Adv."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"721","DOI":"10.6004\/jnccn.2019.0028","article-title":"Acute Myeloid Leukemia, Version 3.2019, NCCN Clinical Practice Guidelines in Oncology","volume":"17","author":"Tallman","year":"2019","journal-title":"J. Natl. Compr. Cancer Netw."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1093\/ajcp\/75.2.140","article-title":"Extramedullary masses as presenting features of acute monoblastic leukemia","volume":"75","author":"Peterson","year":"1981","journal-title":"Am. J. Clin. Pathol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1097\/00043426-200310000-00004","article-title":"Extramedullary leukemia in children with newly diagnosed acute myeloid leukemia: A report from the Children\u2019s Cancer Group","volume":"25","author":"Dusenbery","year":"2003","journal-title":"J. Pediatr. Hematol. Oncol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1007\/BF01715141","article-title":"Granulocytic sarcoma of the prostate as the first manifestation of a late relapse of acute myelogenous leukemia","volume":"68","author":"Thalhammer","year":"1994","journal-title":"Ann. Hematol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1200\/JCO.1993.11.4.690","article-title":"Granulocytic sarcoma is associated with the 8;21 translocation in acute myeloid leukemia","volume":"11","author":"Tallman","year":"1993","journal-title":"J. Clin. Oncol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/j.ijrobp.2018.05.045","article-title":"Use of Radiation in Extramedullary Leukemia\/Chloroma: Guidelines From the International Lymphoma Radiation Oncology Group","volume":"102","author":"Bakst","year":"2018","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1159\/000253592","article-title":"Prognostic factors of treatment outcomes in patients with granulocytic sarcoma","volume":"122","author":"Lan","year":"2009","journal-title":"Acta Haematol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1038\/sj.leu.2402958","article-title":"Outcome in patients with nonleukemic granulocytic sarcoma treated with chemotherapy with or without radiotherapy","volume":"17","author":"Tsimberidou","year":"2003","journal-title":"Leukemia"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1007\/s00277-016-2870-0","article-title":"Evidence for a role of decitabine in the treatment of myeloid sarcoma","volume":"96","author":"Gornicec","year":"2017","journal-title":"Ann. Hematol."},{"key":"ref_28","first-page":"5061","article-title":"Targeted Therapy in FLT3-ITD Positive Myeloid Sarcoma: Proof of Principle","volume":"130","author":"Grillo","year":"2017","journal-title":"Blood"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"2008","DOI":"10.1038\/s41375-018-0056-6","article-title":"Mutational profiling of isolated myeloid sarcomas and utility of serum 2HG as biomarker of IDH1\/2 mutations","volume":"32","author":"Willekens","year":"2018","journal-title":"Leukemia"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1038\/s41408-018-0083-6","article-title":"RTK-RAS pathway mutation is enriched in myeloid sarcoma","volume":"8","author":"Choi","year":"2018","journal-title":"Blood Cancer J."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1200\/JOP.18.00753","article-title":"Venetoclax for Refractory Myeloid Sarcoma","volume":"15","author":"Kanate","year":"2019","journal-title":"J. Oncol. Pract."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1186\/s12905-021-01328-y","article-title":"The myeloid sarcoma treated by Venetoclax with hypomethylating agent followed by stem cell transplantation: Rare case report","volume":"21","author":"Shatilova","year":"2021","journal-title":"BMC Womens. Health"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1007\/s00280-021-04356-5","article-title":"Venetoclax penetrates in cerebrospinal fluid of an acute myeloid leukemia patient with leptomeningeal involvement","volume":"89","author":"Condorelli","year":"2021","journal-title":"Cancer Chemother. Pharmacol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1080\/10428194.2019.1675880","article-title":"PD-1\/PD-L1 expression in extramedullary lesions of acute myeloid leukemia","volume":"62","author":"Meleveedu","year":"2021","journal-title":"Leuk. Lymphoma"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1002\/hon.2506","article-title":"Expression of programmed death ligand 1 is associated with poor prognosis in myeloid sarcoma patients","volume":"36","author":"Kawamoto","year":"2018","journal-title":"Hematol. Oncol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1038\/s41568-019-0116-x","article-title":"The evolving landscape of biomarkers for checkpoint inhibitor immunotherapy","volume":"19","author":"Havel","year":"2019","journal-title":"Nat. Rev. Cancer"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.leukres.2016.12.003","article-title":"Clinical outcome of myeloid sarcoma in adult patients and effect of allogeneic stem cell transplantation. Results from a multicenter survey","volume":"53","author":"Lazzarotto","year":"2017","journal-title":"Leuk. Res."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.blre.2019.04.005","article-title":"Epidemiology of acute myeloid leukemia: Recent progress and enduring challenges","volume":"36","author":"Shallis","year":"2019","journal-title":"Blood Rev."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"100773","DOI":"10.1016\/j.blre.2020.100773","article-title":"Myeloid sarcoma, chloroma, or extramedullary acute myeloid leukemia tumor: A tale of misnomers, controversy and the unresolved","volume":"47","author":"Shallis","year":"2021","journal-title":"Blood Rev."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1016\/0888-7543(91)90270-O","article-title":"Isolation and chromosomal localization of a novel FMS-like tyrosine kinase gene","volume":"9","author":"Rosnet","year":"1991","journal-title":"Genomics"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1016\/0092-8674(91)90010-V","article-title":"A receptor tyrosine kinase specific to hematopoietic stem and progenitor cell-enriched populations","volume":"65","author":"Matthews","year":"1991","journal-title":"Cell"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1532\/IJH97.05090","article-title":"Signal Transduction of Oncogenic Flt3","volume":"82","author":"Choudhary","year":"2005","journal-title":"Int. J. Hematol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1016\/0092-8674(93)90325-K","article-title":"Molecular cloning of a ligand for the flt3\/flk-2 tyrosine kinase receptor: A proliferative factor for primitive hematopoietic cells","volume":"75","author":"Lyman","year":"1993","journal-title":"Cell"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1038\/368643a0","article-title":"Ligand for FLT3\/FLK2 receptor tyrosine kinase regulates growth of haematopoietic stem cells and is encoded by variant RNAs","volume":"368","author":"Hannum","year":"1994","journal-title":"Nature"},{"key":"ref_45","first-page":"1212","article-title":"Expression of the flt3 receptor and its ligand on hematopoietic cells","volume":"9","author":"Brasel","year":"1995","journal-title":"Leukemia"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1038\/sj.leu.2400812","article-title":"Internal tandem duplication of the FLT3 gene is preferentially seen in acute myeloid leukemia and myelodysplastic syndrome among various hematological malignancies. A study on a large series of patients and cell lines","volume":"11","author":"Yokota","year":"1997","journal-title":"Leukemia"},{"key":"ref_47","first-page":"1911","article-title":"Internal tandem duplication of the flt3 gene found in acute myeloid leukemia","volume":"10","author":"Nakao","year":"1996","journal-title":"Leukemia"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1046\/j.1365-2141.2001.02850.x","article-title":"Identification of novel FLT-3 Asp835 mutations in adult acute myeloid leukaemia","volume":"113","author":"Goodeve","year":"2001","journal-title":"Br. J. Haematol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"2193","DOI":"10.1182\/blood.V97.8.2193a","article-title":"Point mutations in the FLT3 gene in AML","volume":"97","author":"Griffin","year":"2001","journal-title":"Blood"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"2434","DOI":"10.1182\/blood.V97.8.2434","article-title":"Activating mutation of D835 within the activation loop of FLT3 in human hematologic malignancies","volume":"97","author":"Yamamoto","year":"2001","journal-title":"Blood"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1038\/s41375-018-0357-9","article-title":"Targeting FLT3 mutations in AML: Review of current knowledge and evidence","volume":"33","author":"Daver","year":"2019","journal-title":"Leukemia"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1182\/blood-2016-08-733196","article-title":"Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel","volume":"129","author":"Estey","year":"2017","journal-title":"Blood"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1182\/asheducation-2013.1.220","article-title":"FLT3 mutations in acute myeloid leukemia: What is the best approach in 2013?","volume":"2013","author":"Levis","year":"2013","journal-title":"Hematol. Am. Soc. Hematol. Educ. Program"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"2744","DOI":"10.1182\/bloodadvances.2018020305","article-title":"Prognostic impact of low allelic ratio FLT3-ITD and NPM1 mutation in acute myeloid leukemia","volume":"2","author":"Sakaguchi","year":"2018","journal-title":"Blood Adv."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.3324\/haematol.2012.062638","article-title":"Activating internal tandem duplication mutations of the fms-like tyrosine kinase-3 (FLT3-ITD) at complete response and relapse in patients with acute myeloid leukemia","volume":"97","author":"Nazha","year":"2012","journal-title":"Haematologica"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.5858\/2009-0292-OA.1","article-title":"FLT3 mutations at diagnosis and relapse in acute myeloid leukemia: Cytogenetic and pathologic correlations, including cuplike blast morphology","volume":"134","author":"McCormick","year":"2010","journal-title":"Arch. Pathol. Lab. Med."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1038\/sj.leu.2404246","article-title":"Stability and prognostic influence of FLT3 mutations in paired initial and relapsed AML samples","volume":"20","author":"Cloos","year":"2006","journal-title":"Leukemia"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"2387","DOI":"10.1182\/blood-2002-01-0195","article-title":"Internal tandem duplication of FLT3 in relapsed acute myeloid leukemia: A comparative analysis of bone marrow samples from 108 adult patients at diagnosis and relapse","volume":"100","author":"Shih","year":"2002","journal-title":"Blood"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"2393","DOI":"10.1182\/blood-2002-02-0420","article-title":"Studies of FLT3 mutations in paired presentation and relapse samples from patients with acute myeloid leukemia: Implications for the role of FLT3 mutations in leukemogenesis, minimal residual disease detection, and possible therapy with FLT3 inhibitors","volume":"100","author":"Kottaridis","year":"2002","journal-title":"Blood"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1182\/blood-2009-09-242859","article-title":"FLT3-mutant allelic burden and clinical status are predictive of response to FLT3 inhibitors in AML","volume":"115","author":"Pratz","year":"2010","journal-title":"Blood"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1038\/modpathol.2012.88","article-title":"Clinical impact of change of FLT3 mutation status in acute myeloid leukemia patients","volume":"25","author":"Warren","year":"2012","journal-title":"Mod. Pathol."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1111\/j.1365-2141.2004.05124.x","article-title":"FLT3 mutations in myeloid sarcoma","volume":"126","author":"Yang","year":"2004","journal-title":"Br. J. Haematol."},{"key":"ref_63","doi-asserted-by":"crossref","unstructured":"Fukuda, S., Onishi, C., and Pelus, L.M. (2011). Trafficking of Acute Leukemia Cells\u2014Chemokine Receptor Pathways that Modulate Leukemia Cell Dissemination. Acute Leukemia-The Scientist\u2019s Perspective and Challenge, IntechOpen.","DOI":"10.5772\/20448"},{"key":"ref_64","first-page":"44","article-title":"Molecular and cellular aspects of extramedullary manifestations of acute myeloid leukemia","volume":"2","author":"Mohammadiasl","year":"2016","journal-title":"J. Cancer Metastasis Treat."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1056\/NEJMoa1614359","article-title":"Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a FLT3 Mutation","volume":"377","author":"Stone","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1016\/S1470-2045(17)30416-3","article-title":"Selective inhibition of FLT3 by gilteritinib in relapsed or refractory acute myeloid leukaemia: A multicentre, first-in-human, open-label, phase 1-2 study","volume":"18","author":"Perl","year":"2017","journal-title":"Lancet Oncol."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"1951","DOI":"10.1517\/13543784.12.12.1951","article-title":"Novel FLT3 tyrosine kinase inhibitors","volume":"12","author":"Levis","year":"2003","journal-title":"Expert Opin. Investig. Drugs"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"1989","DOI":"10.1016\/j.bbmt.2014.08.015","article-title":"Improved FLT3 internal tandem duplication PCR assay predicts outcome after allogeneic transplant for acute myeloid leukemia","volume":"20","author":"Grunwald","year":"2014","journal-title":"Biol. Blood Marrow Transplant."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1007\/s12185-020-02855-4","article-title":"Successful treatment with gilteritinib for isolated extramedullary relapse of acute myeloid leukemia with FLT3-ITD mutation after allogeneic stem cell transplantation","volume":"112","author":"Kida","year":"2020","journal-title":"Int. J. Hematol."},{"key":"ref_70","first-page":"100219","article-title":"Targeted therapy for medullary and extramedullary relapse of FLT3-ITD acute myeloid leukemia following allogeneic hematopoietic stem cell transplantation","volume":"14","author":"Kumode","year":"2020","journal-title":"Leuk. Res. Rep."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1159\/000518356","article-title":"A Relapsing Meningeal Acute Myeloid Leukaemia FLT3-ITD+ Responding to Gilteritinib","volume":"66","author":"Perrone","year":"2021","journal-title":"Chemotherapy"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1001\/jamaophthalmol.2020.0110","article-title":"An Iridociliochoroidal Myeloid Sarcoma Associated With Relapsed Acute Myeloid Leukemia With FLT3-ITD Mutation, Treated With Gilteritinib, an FLT3 Inhibitor","volume":"138","author":"Kim","year":"2020","journal-title":"JAMA Ophthalmol."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1007\/s00277-021-04702-w","article-title":"Molecular testing of isolated myeloid sarcoma allows successful FLT3-targeted therapy","volume":"101","author":"Shallis","year":"2021","journal-title":"Ann. Hematol."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1016\/j.leukres.2009.10.001","article-title":"Outcome of patients with FLT3-mutated acute myeloid leukemia in first relapse","volume":"34","author":"Ravandi","year":"2010","journal-title":"Leuk. Res."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1158\/1535-7163.MCT-16-0876","article-title":"FLT3 Inhibitors in Acute Myeloid Leukemia: Current Status and Future Directions","volume":"16","author":"Baer","year":"2017","journal-title":"Mol. Cancer Ther."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"3679","DOI":"10.1182\/blood-2004-06-2459","article-title":"FLT3-ITD-TKD dual mutants associated with AML confer resistance to FLT3 PTK inhibitors and cytotoxic agents by overexpression of Bcl-x(L)","volume":"105","author":"Bagrintseva","year":"2005","journal-title":"Blood"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"4063","DOI":"10.1182\/blood-2007-11-126664","article-title":"A novel molecular mechanism of primary resistance to FLT3-kinase inhibitors in AML","volume":"113","author":"Breitenbuecher","year":"2009","journal-title":"Blood"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"1763","DOI":"10.1038\/sj.leu.2404776","article-title":"BH3 mimetic ABT-737 neutralizes resistance to FLT3 inhibitor treatment mediated by FLT3-independent expression of BCL2 in primary AML blasts","volume":"21","author":"Kohl","year":"2007","journal-title":"Leukemia"},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"2443","DOI":"10.1182\/blood-2013-03-491431","article-title":"Axl, a prognostic and therapeutic target in acute myeloid leukemia mediates paracrine crosstalk of leukemia cells with bone marrow stroma","volume":"122","author":"Schultze","year":"2013","journal-title":"Blood"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"3286","DOI":"10.1182\/blood-2010-01-266742","article-title":"FLT3 ligand impedes the efficacy of FLT3 inhibitors in vitro and in vivo","volume":"117","author":"Sato","year":"2011","journal-title":"Blood"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"3294","DOI":"10.1182\/blood-2010-08-301796","article-title":"Results from a randomized trial of salvage chemotherapy followed by lestaurtinib for patients with FLT3 mutant AML in first relapse","volume":"117","author":"Levis","year":"2011","journal-title":"Blood"},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"6471","DOI":"10.1158\/0008-5472.CAN-15-3569","article-title":"FGF2 from Marrow Microenvironment Promotes Resistance to FLT3 Inhibitors in Acute Myeloid Leukemia","volume":"76","author":"Traer","year":"2016","journal-title":"Cancer Res."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"2306","DOI":"10.1002\/eji.201344313","article-title":"Static and dynamic components synergize to form a stable survival niche for bone marrow plasma cells","volume":"44","author":"Zehentmeier","year":"2014","journal-title":"Eur. J. Immunol."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.1084\/jem.20131800","article-title":"Indigenous enteric eosinophils control DCs to initiate a primary Th2 immune response in vivo","volume":"211","author":"Chu","year":"2014","journal-title":"J. Exp. Med."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"5935","DOI":"10.4049\/jimmunol.164.11.5935","article-title":"Expression of CXCR4 in Eosinophils: Functional Analyses and Cytokine-Mediated Regulation","volume":"164","author":"Nagase","year":"2000","journal-title":"J. Immunol."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"31053","DOI":"10.1074\/jbc.M114.568287","article-title":"Internal tandem duplication mutations in FLT3 gene augment chemotaxis to Cxcl12 protein by blocking the down-regulation of the Rho-associated kinase via the Cxcl12\/Cxcr4 signaling axis","volume":"289","author":"Onish","year":"2014","journal-title":"J. Biol. Chem."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"1957","DOI":"10.1084\/jem.20082074","article-title":"Dissection of PIM serine\/threonine kinases in FLT3-ITD\u2013induced leukemogenesis reveals PIM1 as regulator of CXCL12\u2013CXCR4-mediated homing and migration","volume":"206","author":"Grundler","year":"2009","journal-title":"J. Exp. Med."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1038\/nature11016","article-title":"Validation of ITD mutations in FLT3 as a therapeutic target in human acute myeloid leukaemia","volume":"485","author":"Smith","year":"2012","journal-title":"Nature"}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/14\/9\/2186\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T23:02:07Z","timestamp":1760137327000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/14\/9\/2186"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4,27]]},"references-count":88,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2022,5]]}},"alternative-id":["cancers14092186"],"URL":"https:\/\/doi.org\/10.3390\/cancers14092186","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,4,27]]}}}